{'fraction_non_alphanumeric': 0.027217182003332716, 'fraction_numerical': 0.026615441584891687, 'mean_word_length': 5.167570653725378, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 2, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer.

Increased expression of ubiquitin-conjugating enzyme E2T (UBE2T) is reported in human prostate cancer. However, whether UBE2T plays any functional role in prostate cancer development remains unknown. We here report the first functional characterization of UBE2T in prostate carcinogenesis. Prostate cancer tissue array analysis confirmed upregulation of UBE2T in prostate cancer, especially these with distant metastasis. Moreover, higher level of UBE2T expression is associated with poorer prognosis of prostate cancer patients. Ectopic expression of UBE2T significantly promotes prostate cancer cell proliferation, motility and invasion, while UBE2T depletion by shRNA significantly inhibits these abilities of prostate cancer cells. Xenograft mouse model studies showed that overexpression of UBE2T promotes whereas UBE2T depletion inhibits tumor formation and metastasis significantly. Collectively, we identify critical roles of UBE2T in prostate cancer development and progression. These findings may serve as a framework for future investigations designed to more comprehensive determination of UBE2T as a potential therapeutic target.


INTRODUCTION
Prostate cancer (PCa) is the most frequent mali gnancy in men worldwide. The clinical behaviors range from slowly growing indolent tumors to highly aggressive, metastatic cancers. The pathologic stages of PCa begin with abnormal epithelial proliferation and prostatic intraepithelial neoplasia with progression to invasive carcinoma and eventually metastatic diseases [1]. While early localized disease is usually curable, the survival rate drops to only 34% with progression to invasive and metastatic disease [2]. For the initiation of PCa, researchers have found a number of genes or their alternations that promoted the progression of PCa [3][4][5][6]. However, with highly heterogeneous nature of PCa, unraveling the molecular and biological processes that contribute to PCa development and progression still remains as a challenging task.
We attempted to identify the aberrant expression of some genes in PCa using bioinformatics analysis of public available dataset and found that a novel gene UBE2T (ubiquitin-conjugating enzyme E2T) is significantly correlated with the diseasefree survival of PCa patients. UBE2T is reported to participate in the DNA repair pathway and activate monoubiquitination of FANCD2 which is essential for the activation of FA core pathway [7,8]. UBE2T has been also found overexpressed in lung [9,10], bladder [11] and prostate cancers [12] and may act as oncogenelike gene in breast cancer by repressing BRCA1 expression and promoting the proliferation and transformation of breast cancer cells [13]. However, whether UBE2T plays any functional role in PCa has not been reported.
In this study, we focused on elucidating the signi ficant role of UBE2T in prostate carcinogenesis. We showed that UBE2T is frequently found overexpressed in primary PCa, especially in patients with distant metastasis. Moreover, UBE2T expression level is correlated with poor patient diseasefree survival. We further demonstrated that UBE2T promotes proliferation, invasion, tumor formation and metastasis of PCa cells. These data indicated that UBE2T is a novel oncogene and a potential therapeutic target for PCa. www.impactjournals.com/oncotarget

Overexpression of UBE2T in prostate cancers is positively correlated with metastasis and poor prognosis
We first confirmed whether UBE2T expression level was elevated in PCa by immunochemical staining of UBE2T in a tissue microarray. As shown in Figure 1A, UBE2T expression was hardly detectable in normal prostate tissue, but overexpressed in PCa tissue and most highly expressed in metastatic PCa tissue. Quantification analyses showed significant differences among different status of PCa ( Figure 1B).
To evaluate whether UBE2T was related with prognosis of PCa patients, we carried out the bioinformatics analysis of the publicly available dataset (GSE21032). The PCa patients were divided into tertiles based on UBE2T expression levels (low = bottom tertile, intermediate = middle tertile, and high = top tertile). It was found that the patients with higher UBE2T mRNA level in PCa tissues had poorer disease free survival (DFS) than those with lower UBE2T expression level ( Figure 1C) suggesting that UBE2T expression significantly correlated with the prognosis of PCa patients.

UBE2T promotes prostate cancer cell proliferation
To better understand the role of UBE2T in PCa, we used retroviral vectors to establish PCa cell lines stably overexpressing or silencing UBE2T. The expression levels of UBE2T in the subsequent cell lines were examined by Western blotting (Figure 2A and Supplementary Figure  S1A). We first used 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and colony formation assays to investigate a growthpromoting effect of UBE2T on PCa cells. MTT assay revealed that Du145, PC3 and LNCaP cells with overexpression of UBE2T proliferated more rapidly than their corresponding control cells ( Figure  2B and Supplementary Figure S1B). In colony formation assay, overexpression of UBE2T in Du145 ( Figure 2D), PC3 ( Figure 2E) and LNCaP (Supplementary Figure S1C) cells significantly increased the numbers and sizes of clones. In contrast, silencing UBE2T expression by two shRNAs targeting UBE2T (shUBE2T A and D) in Du145 and PC3 cells dramatically suppressed the growth ( Figure 2C, 2F and 2G) of both cell lines in a dosedependent manner as shUBE2T.D suppressed the growth more dramatically than shUBE2T.A which are in concordance with the knockdown efficacy on UBE2T in Du145 cells.

UBE2T enhances the tumor growth in prostate cancer xenograft mouse model
In order to confirm whether the growth-promoting effect of UBE2T observed in cultured cells is relevant to prostate tumor growth in vivo, Du145 cells with ectopic or silent expression of UBE2T were subcutaneously inoculated into BALB/C athymic mice respectively. Overexpression of UBE2T significantly accelerated tumor growth ( Figure 3A) and induced an increase in tumor weight ( Figure 3B) and volume ( Figure 3C). In contrast, silencing UBE2T expression inhibited tumor growth ( Figure 3D) and induced a decrease in tumor weight ( Figure 3E) and volume ( Figure 3F). Taking all together, we concluded that UBE2T promotes the proliferation of PCa cells in vivo and in vitro.

UBE2T induces epithelial-mesenchymal transition in prostate cancer cells
We observed changes in cell morphology after UBE2T overexpression. Under microscope, both Du145 and PC3 cells overexpressing UBE2T showed mesenchymal morphology compared with control cells ( Figure 4A). By H&E staining for tumors formed in xenograft mouse model, we found that tumor cells overexpressing UBE2T showed mesenchymallike morphology ( Figure 4B). This indicated that UBE2T possibly induces epithelialmesenchymal transition (EMT) of PCa cells. To further confirm these observations, we assessed protein markers of EMT. As shown in Figure 4C, downregulation of epithelial cell marker (Ecadherin) and upregulation of mesenchymal cell markers (vimentin, fibronection and alpha-smooth muscle action) were detected by Western blotting in UBE2T overexpressing cells, and the same results were found through immunofluorescence analyses ( Figure 4D and 4E). We further confirmed this EMT marker expression pattern change in xenograft tumor sections through immunochemical staining ( Figure 4F and 4G). Moreover, we found similar expression pattern of EMT marker in androgendependent LNCaP cells with overexpression of UBE2T by Western blotting (Supplementary Figure S2A). These results collectively indicated that UBE2T promotes EMT of PCa cells.

UBE2T accelerates prostate cancer cell migration and invasion
We then evaluated the effects of UBE2T on migration and invasion of PCa cells. Scratch assay revealed that UBE2T significantly accelerated wound healing of Du145 ( Figure 5A), PC3 ( Figure 5B) and LNCaP (Supplementary Figure S2B) cells while silencing UBE2T decreased the rate of migration ( Figure 5C and 5D). To further confirm the role of UBE2T in migration, transwell assay was carried out. Overexpression of UBE2T promoted more cells migrated through the membrane to the bottom of the aperture ( Figure 6A and Supplementary Figure S2C). In contrast, silencing UBE2T expression restrained this progress ( Figure 6B). Moreover, matrigel assay was used to evaluate the invasive potential of PCa cells with altered UBE2T expression. As shown in Figure 6C and Supplementary Figure S2C, ectopic expression of UBE2T www.impactjournals.com/oncotarget significantly enhanced the invaded rate of PCa cells while silencing UBE2T expression decreased the number of invaded PCa cells ( Figure 6D). These results revealed that UBE2T promotes migration and invasion of PCa cells.

UBE2T promotes prostate cancer cell metastasis in vivo
To examine whether the function of UBE2T in migration and invasion in vitro was relevant to metastasis of PCa cells in vivo, Du145 cells with ectopic or silent UBE2T expression were inoculated into tail vein of BALB/C athymic mice respectively. 60 days later, we observed that more mice injected with PCa cells overexpressing UBE2T had distant metastasis ( Figure 7A). In addition, more metastasis foci in lung ( Figure 7B) and liver ( Figure 7C) were counted in each mouse injected with PCa cells overexpressing UBE2T. On the contrary, silencing UBE2T expression decreased the number of metastatic mice ( Figure 7A) and metastatic foci in lung ( Figure 7D) and liver ( Figure 7E).
Collectively, both in vivo and in vitro data strongly showed the biological role of UBE2T as a promoter of tumor growth and an inducer of EMT and metastasis in PCa.

A positive correlation between UBE2T and vimentin expression in human prostate cancer
As shown above, we found that vimentin expression level is elevated in the PCa cells with overexpressing  To further confirm the relationship between UBE2T and vimentin, vimentin expression was analyzed in a tissue array. As shown in Figure 8B, vimentin expression was found high in PCa tissues with distant metastasis, moderate in PCa tissues without distant metastasis and low in normal prostate tissue, indicating vimentin expression was associated with metastasis of PCa ( Figure 8C). In linear correlation analysis, UBE2T expression level was positively correlated with that of vimentin ( Figure 8D).

DISCUSSSION
UBE2T is a new member of ubiquitinconjugating enzymes [14]. This study, for first time, indicated that UBE2T acts as an oncogene in PCa. We found that UBE2T expression is elevated in PCa and higher level of UBE2T is associated with poorer prognosis of PCa patients. Overexpression of UBE2T in PCa cells robustly promotes cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo. Of note, we discovered a positive correlation between UBE2T and vimentin expression, both expression levels of UBE2T and vimentin are associated with the malignant properties of prostate tumors.  UBE2T was previously reported as essential for the monoubiquitination of FANCD2 protein which was the key step of DNA repair in Fancini anemia [7]. The putative role of UBE2T as an oncogene in cancer development was supported by the observations that aberrant expression of UBE2T in bladder, lung and prostate cancers [10][11].
The fact that UBE2T locates at 1q32.1 and the gain of 1q can been observed in most cancers [15][16][17][18], which may result in the increased expression of UBE2T, leads further support to the possibility of UBE2T as an oncogene. Perhaps the most convincing evidence is that downregulation of BRCA1 by UBE2T in breast cancer significantly promoted proliferation and tumor growth of breast cancer cells. Consistent with these reports, we showed that UBE2T overexpression promotes PCa cell proliferation and enhanced tumor growth in vivo. More important, we pointed out a novel functional role of UBE2T in metastasis by regulating EMT of PCa cells.
In this study, PCa cells with overexpression of UBE2T displayed a mesenchymal phenotype with the enhanced potentials of migration and invasion in vitro. Consistent with the notion that EMT is essential for tumor cells separating from the solid tumors and invading into distant sites, all of these Multiple EMT regulators have been extensively reported. Among them, vimentin is the mammalian intermediate filament proteins that is ubiquitously expressed in normal mesenchymal cells [19] and often used as a marker of cells undergoing EMT during both normal development and metastatic progression. In this study, we revealed that both UBE2T and vimentin expressions were closely related with metastatic abilities of PCa and there is a positive relationship between UBE2T and vimentin through linear correlation analysis. Interestingly, UBE2T elevated vimentin expression in PCa cells. Since vimentin was proved to be a regulator of cell adhesion by affecting formation and turnover adhesion structures [20][21][22][23][24][25] and associated with cancer migration [26,27], we speculate vimentin may be a potential downstream protein of UBE2T in UBE2T induced EMT and metastasis. Considering that UBE2T is an ubiquitinconjugating enzyme, we speculate that UBE2T may upregulate vimentin level through a more complex indirect mechanism. Further determination of the interaction between UBE2T and vimentin may not only provide more details to the function of UBE2T, but may also reveal a novel therapeutic target in PCa by disrupting the interaction between UBE2T and vimentin.
UBE2T may be a novel indicator of PCa along with about 900 000 new PCa patients diagnosed every year [28]. Nowadays, the most important diagnostic and prognostic indicators of PCa are stage, pretherapy PSA level, and Gleason score (GS) [29]. Unfortunately, misdiagnosis was unavoidable on account of that PCA3 is not only specially overexpressed in PCa [30,31] but also elevated in the presence of prostate disorders [30] and overdiagnosis was made because of the limitation of GS which is given to PCa based upon its microscopic appearance [28]. Either misdiagnosis or overdiagnosis could cause people experience the side effects of treatment. Interestingly, UBE2T is only overexpressed in PCa, and plays an important role in PCa metastasis which is the main cause of PCa death, UBE2T could be a better diagnostic and prognostic indicator of PCa patients.
In summary, we have for the first time achieved that UBE2T overexpression was sufficient to induce EMT of PCa cells as well as promote tumor growth and metastasis in vivo. We also preliminarily revealed that UBE2T acts as an oncogene, at least in part, through cooperating with vimentin. Together with all the results, our studies suggested UBE2T as a promising prognostic and therapeutic target in PCa.

Cell culture and retroviral transduction
PCa cell lines PC3, Du145 and LNCaP were maintained in RPMI1640 (HyClone) with Lglutamine. Phoenix packaging cell and 293T were maintained in high glucose DMEM medium (HyClone). All medium was supplemented with 10 percents fetal bovine serum (TBD) and 1 percent penicillin/streptomycin (Solarbio). The cell lines were incubated at 37°C in 5% CO 2 .

RNA isolation and reverse transcription PCR
Cells were incubated in 60 mm dishes (Corn ing) and Trizol (Invitrogen) was added at 70% density after PBS washing followed RNA isolation accor ding to trizol introductions. After concentration de tection of total RNA extraction, 3 μg RNA was pipetted for RTPCR (Applied Biosystems, Thermal Cycler) of UBE2T using the primers: forward primer 5′-CAAATATTAGGTGGAGCCAACAC-3′ and reverse primer 5′-TAGATCACCTTGGCAAAGAACC-3′, and agarose gel electrophoresis followed at 120 V for 30 min.

Proliferation assay
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide, Solarbio, M8180) assay and Colony Formation were used to detect the proliferative rate of UBE2Toverexpression or UBE2Tknockdown cell lines. For MTT assay, 1000 cells were plated into 96 well plate and cultured at 37°C in a. MTT was dropped at 70% density and the 96well plate was incubated for 4 hours followed 150 μl DMSO dropped after removing the supernatant carefully. The OD values were measured by the machine (Multiskan 3). In Colony formation, 800 cells were plated into 60 mm dishes and incubated for 2 weeks in a homogeneous atmosphere with 5% CO 2 at 37°C. Then the clones were fixed by methal alcohol and) stained for 30 minutes in Giemsa (Sigma, GS-500) followed ddH 2 O washed. The clones were counted under a microscope.

Migration assay
Scratch assay and transwell assay to detect the migrated ability. Scratch assay was performed by a 200 μl pipette in 60 mm dishes when cells grew up to 90-100% density. And the floated cells were removed with twice Hank's (Beyotime, C0218) washes, and wound pictures were taken at 0 hour, 24 hours and 48 hours by Olympus IX70 inverted microscope. In transwell assay, bottom chamber was filled with 1 ml RPMI-1640 with 10% fetal bovine serum and 1% penicillin/streptomycin and the top chamber was filled with the same media with 4 × 10 4 (PC3 cells with ectopic expression of UBE2T) or 2 × 10 4 (Du145 cells with ectopic expression of UBE2T) or 4 × 10 4 (LNcaP cells with ectopic expression of UBE2T) cells suspended. The cells were incubated for 48 hours and the fixed in methanol longer than 30 minutes and stained with Giemsa stain after the cells on the top surface of membrane removed by cotton swab. The pictures were taken by Olympus IX70 inverted microscope and the numbers of migrated cells were counted.

Invasion assay
The chambers (BD, 3097) were coated with matrigel (BD, 354605) and incubated for longer than 30 minutes at 37°C to perform invasion assay. The bottom chambers were filled with 1 ml RPMI-1640 with 10% fetal bovine serum and 1% penicillin/streptomycin and the top chamber were filled with 200 μl RPMI-1640 without FBS or antibiotics but with 10 5 (PC3 cells with ectopic expression of UBE2T) or 6 × 10 4 Du145 cells with ectopic expression of UBE2T or 8 × 10 4 (LNcaP cells with ectopic expression of UBE2T) suspended cells. Cells were incubated in the incubator for 48 hours. The noninvaded cells on the top surface of membrane were removed by cotton swab and the invaded cells were fixed in methanol longer than 30 minutes and stained with Giemsa stain for 30 minutes. The pictures were taken by Olympus IX70 inverted microscope. The invaded cells were counted.

Immunofluorescence
Cells with altered expression of UBE2T were cultured on glass coverslips (NEST, 801007) in 24well plate and fixed by 4% paraformaldehyde for 15 min at 50-60% density followed by washing in PBS. After blocking in goat serum (1:10 in PBS) for 30 min, the coverslips were incubated with primary antibodies (diluted in primary stain diluting buffer, Beyotime, P0103) overnight at 4°C and secondary antibodies 1 hour at 37°C. Nuclei were visualized by 4,6diamidine2phenylindole staining (DAPI, Solarbio, D8200). The coverslips touched face down a drop of Antifade Mounting Medium (Beyotime, P0126) on a slide and the fluorescence was captured by laser scanning confocal microscopy.

Immunohistochemical staining
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissues or prostate array from Alenabio, China PR483a. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Antigen retrieval was carried out in citrate buffer (10 mM, pH6) for 20 min at more than 92°C. Tissue sections were incubated first with the primary antibodies of UBE2T (1:50, Cell Signaling Technology), vimentin (1:50, Cell Signaling Technology) for 16 h at 4°C and then incubated for 30 minutes at 37°C and then subsequently with a secondary biotinylated antibody (SP9000, China) for 30 minutes at 37°C followed by incubation with streptavidin-peroxidase complex for 5 min at room temperature.

In vivo tumor growth and metastasis
Nude mice were purchased from Shanghai Slac Laboratory Animal Co. Ltd. and maintained in microisolator cages. All animals were used in accordance with institutional guidelines and the current experiments were approved by the Use Committee for Animal Care. For subcutaneous inoculation, different numbers of tumor cells (1 million Du145-UBE2T and control cells, 5 million Du145-shUBE2T and control cells) resuspended in PBS medium and inoculated subcutaneously into 8weekold nude mice. The tumors were measured every 3 days after appearance of tumors and the tumor volume was calculated by the formula length × width2/2. The mice were killed 44 days after the inoculation. For metastasis assays, cells were resuspended in PBS at a concentration of 3 × 10 7 cells/ml. Cell suspension (0.1 ml) was injected into tail veins of nude mice. All of the mice were killed by CO 2 60 days after inoculation.

Statistical analysis
Statistical analysis Data were described as the mean ± SD. Association between UBE2T and vimentin expression in prostate tissue microarray was assessed using the Spearman rank correlation test. DFS was estimated using the Kaplan-Meier method. The relationship between survival period and each of the variables was analyzed using the logrank test for categorical variables. Comparisons between different groups were undertaken using the Student twotailed t test. The criterion of statistical significance was P < 0.05. Statistical analysis was done with SPSS/Win11.0 software (SPSS Inc.).